Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

: Prostate cancer is the most frequently diagnosed cancer among men in Italy, yet no national population-based screening program exists. In response to new European Council recommendations, the Lombardy Region launched a pilot in November 2024 to assess the feasibility of a digitally enabled, risk-adapted screening model. : Men turning 50 were invited to voluntarily self-enroll through the regional electronic health record (FSE). A digital questionnaire assessed eligibility and family history (FH); eligible individuals (97,849 men without a PSA test in the past two years in the regional database) were offered free PSA testing. Risk stratification guided follow-up: men with PSA >3 ng/mL or a positive FH were referred to urology; others were assigned 2- or 5-year recall based on PSA level. : By June 2025, 8558 men had enrolled (8.7% uptake), 6072 were eligible; 644 (10.6%) reported a positive FH. Among those tested, 58.4% had PSA < 1 ng/mL and were FH-negative, 25.8% had PSA > 1 and <3 ng/mL and were FH-negative, and 15.9% met referral criteria. Digital triage was efficient and ensured care continuity without burdening specialists. Participation varied by local health authority (ATS), depending on implementation context. Preliminary data show a 25.9% reduction in urology consultations and a 35% reduction in MRI use compared to standard care, with no biopsy rate increase. : The pilot demonstrates the technical feasibility, safety, low administrative burden, and potential sustainability of digital, risk-stratified prostate cancer screening. While participation was low without active invitations, early results support expansion with improved outreach. Lombardy's experience offers a scalable, EU-aligned model for broader implementation across Italy and other health systems seeking to balance early detection with resource efficiency.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12385802PMC
http://dx.doi.org/10.3390/healthcare13162041DOI Listing

Publication Analysis

Top Keywords

prostate cancer
8
screening model
8
lombardy region
8
men psa
8
psa ng/ml
8
psa
6
men
5
early activation
4
activation multilevel
4
multilevel prostate
4

Similar Publications

Background: With the advancement of MR-based imaging, prostate cancer ablative therapies have seen increased interest to reduce complications of prostate cancer treatment. Although less invasive, they do carry procedural risks, including rectal injury. To date, the medicolegal aspects of ablative therapy remain underexplored.

View Article and Find Full Text PDF

Background: Docetaxel is the most common chemotherapy regimen for several neoplasms, including advanced OSCC (Oral Squamous Cell Carcinoma). Unfortunately, chemoresistance leads to relapse and adverse disease outcomes.

Methods: We performed CRISPR-based kinome screening to identify potential players of Docetaxel resistance.

View Article and Find Full Text PDF

Effects of a Patient Decision Aid for Nonmetastatic Prostate Cancer Established in Routine Care: The Randomized Controlled EvEnt-PCA Trial.

Eur Urol Focus

September 2025

Department of Urology, Medical Centre, University of Heidelberg, Heidelberg, Germany; Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany; Department of Urology, Philipps-University Marburg, Marburg, Germany.

Background And Objective: Since 2016, >21 000 patients with prostate cancer (PC) used our personalized online decision aid in routine care in Germany. We analyzed the effects of this online decision aid for men with nonmetastatic PC in a randomized controlled trial.

Methods: In the randomized controlled EvEnt-PCA trial, 116 centers performed 1:1 allocation of 1115 patients with nonmetastatic PC to use an online decision aid (intervention = I) or a printed brochure (control = C).

View Article and Find Full Text PDF